Pediatrics
Non-viral hepatitis
An elevated ALT identifies hepatocyte injury. Use age, exposures, IgG, antibodies and histology to work out why it occurred.
Partially covered in the main question banks · 18 main-bank entries · 40 linked PDF entries · 0 generated drills
Prerequisites and related lessons
- Liver function tests (LFT)
Curriculum reference · Official College Textbook – Digestive Disorders – Part 2, pp. 115–117. Lesson adapted from Pediatric hepatology and metabolic disease.
Topic map
- Recognizeacute or chronic hepatocellular injury
- Autoimmunetype 1 ANA/SMA or type 2 LKM1/LC1
- AlternativesWilson, metabolic, drug-induced, ischemic
- Confirm contextexclude mimics, biopsy when safe, treat cause
Scroll the diagram to see all labels.
Definition and differential
Non-viral hepatitis means hepatic inflammation from causes other than viral infection. Evaluate autoimmune hepatitis (AIH), drug-induced liver injury, Wilson disease, metabolic disorders such as alpha-1 antitrypsin deficiency and selected inherited diseases, steatotic liver disease, hypoxic/ischemic injury and other systemic causes. Distinguish hepatocellular injury (ALT/AST predominant) from cholestatic or mixed patterns. History should cover timing, drugs including acetaminophen and supplements, infections, autoimmune or family history, travel, obesity/metabolic risk and shock. A hepatitic biochemical pattern alone cannot identify the cause.
AIH is immune attack on hepatocytes in genetically susceptible patients, with loss of immune tolerance and possible environmental triggers. Book II notes a female predominance around 75% in the course [IM Dept Q1] and associations with other autoimmune disease such as thyroiditis, celiac disease and inflammatory conditions. Both types occur in children, with type 2 often presenting younger and sometimes acutely or severely. Symptoms range from asymptomatic elevations to fatigue, malaise, jaundice, hepatomegaly and acute liver failure. Chronic disease may present with cirrhosis, portal hypertension or cytopenias. Autoimmune sclerosing cholangitis can overlap, especially with cholestatic features or inflammatory bowel disease.
Serology, histology and diagnosis
- Initial assessment
- ALT/AST, IgG, autoantibodies, exposure history and synthetic function
- Confirmation or next test
- Exclude mimics and seek compatible biopsy findings when safe
The classic pattern is marked ALT/AST and raised IgG [Pediatric Mid Q1 · IM Dept Q2/Q5 · Old], with possible bilirubin elevation and relatively smaller ALP/GGT elevations. Type 1: ANA and/or anti-smooth muscle antibody (SMA/ASMA) [Pediatric Mid Q2 · IM Dept Q3]. Type 2: anti-LKM1 and/or anti-LC1 [Formative Q8 · IM Dept Q4]. Anti-LKM1 targets CYP2D6 [IM Dept Q4]. Anti-SLA can be helpful in selected cases. Children can have clinically relevant lower titers than adults. Normal IgG or negative antibodies do not completely exclude AIH. Positive antibodies are not sufficient in isolation.
Check for viral hepatitis and differentiate Wilson disease, drug-induced autoimmune-like hepatitis and other mimics. With concerning liver function, evaluate INR, glucose, bilirubin, albumin and clinical encephalopathy promptly. A liver biopsy showing interface hepatitis, piecemeal necrosis and often plasma cells [Pediatric Mid Q3 · IM Dept Q6 · Old] supports diagnosis and stages fibrosis. Interface means inflammation crosses from a portal tract into nearby hepatocytes. This pattern is supportive, not unique to AIH. Assess bile ducts via cholangiographic imaging if autoimmune sclerosing cholangitis is suspected.
Management and follow-up
Induce remission with prednisolone or prednisone [IM Dept Q7 · Old p. 92 Q34] under pediatric hepatology supervision, then taper according to clinical response, aminotransferases and IgG. Azathioprine [IM Dept Q8] is a steroid-sparing or maintenance agent. Assess suitability, TPMT/NUDT15 status where used, CBC and liver tests, and individualize timing with severe jaundice or decompensation. The IM department’s 30 mg starting dose is the adult-oriented course answer. Pediatric regimens are weight-based and specialist-directed. The text quotes >80% remission with therapy. Relapse is common after stopping; the course’s 2–3 years of remission before possible withdrawal [IM Dept Q9–10] is an exam anchor, while actual decisions require prolonged stable biochemical remission and specialist criteria.
Budesonide is inappropriate in cirrhosis. Selected refractory or intolerant patients may receive mycophenolate, tacrolimus or other specialist therapies. Monitor steroid effects, blood counts, growth, bone health, adherence and relapse. Escalate decompensated or nonresponding severe disease for transplant evaluation when appropriate. Treat any alternative cause directly. Acetaminophen toxicity warrants urgent toxicology assessment and N-acetylcysteine [Clinical acute liver failure reference]. Suspected drug-induced injury requires stopping the culprit, evaluating severity and reporting where appropriate.
Exam traps
IgG and hepatocellular enzymes favor AIH. Dominant ALP/GGT elevation suggests a cholestatic process or overlap. Anti-mitochondrial antibody points toward primary biliary cholangitis, uncommon in children and separate from usual AIH. Wilson disease can mimic AIH and should be considered before attributing all injury to autoimmunity.
Diagnostic and management pathways
- Elevated ALT/AST → assess INR, glucose, symptoms and exposure history
- Exclude infection and metabolic/drug causes → IgG and age-appropriate autoantibodies
- AIH suspected → histology when safe, assess biliary overlap if indicated
- Confirmed → steroid induction with a tailored maintenance plan → monitor remission/relapse and complications
Compare at a glance
| Cause or subtype | Key lab or clue | Confirmation direction |
|---|---|---|
| AIH type 1 | ANA/SMA and often high IgG | Compatible biopsy and exclusion of mimics |
| AIH type 2 | Anti-LKM1/LC1, often younger or acute | Compatible clinical/serological and biopsy findings |
| Wilson disease | Low ceruloplasmin, high urine copper, neurologic signs | Integrated copper studies and ATP7B evaluation |
| Drug-induced injury | Compatible exposure and timing | Identify culprit, exclude alternatives, assess severity |
| Autoimmune sclerosing cholangitis | AIH features plus ductal or cholestatic clues | Cholangiographic assessment and specialist review |
Supplementary clarification – not directly stated in the uploaded materials. Clinical references · ESPGHAN pediatric autoimmune liver disease statement · NASPGHAN pediatric acute liver failure position paper
Exam words
- around 75% in the course [IM Dept Q1]
- marked ALT/AST and raised IgG [Pediatric Mid Q1 · IM Dept Q2/Q5 · Old]
- Type 1: ANA and/or anti-smooth muscle antibody (SMA/ASMA) [Pediatric Mid Q2 · IM Dept Q3]
- Type 2: anti-LKM1 and/or anti-LC1 [Formative Q8 · IM Dept Q4]
- CYP2D6 [IM Dept Q4]
- liver biopsy showing interface hepatitis, piecemeal necrosis and often plasma cells [Pediatric Mid Q3 · IM Dept Q6 · Old]
- prednisolone or prednisone [IM Dept Q7 · Old p. 92 Q34]
- Azathioprine [IM Dept Q8]
- 2–3 years of remission before possible withdrawal [IM Dept Q9–10]
- N-acetylcysteine [Clinical acute liver failure reference]
Practice questions
Rapid revision sheet
Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.
- around 75% in the course [IM Dept Q1]
- marked ALT/AST and raised IgG [Pediatric Mid Q1 · IM Dept Q2/Q5 · Old]
- Type 1: ANA and/or anti-smooth muscle antibody (SMA/ASMA) [Pediatric Mid Q2 · IM Dept Q3]
- Type 2: anti-LKM1 and/or anti-LC1 [Formative Q8 · IM Dept Q4]
- CYP2D6 [IM Dept Q4]
- liver biopsy showing interface hepatitis, piecemeal necrosis and often plasma cells [Pediatric Mid Q3 · IM Dept Q6 · Old]
Official College Textbook – Digestive Disorders – Part 2, pp. 115–117
Active recall
What serology distinguishes type 1 from type 2 autoimmune hepatitis?
ANA and/or smooth-muscle antibodies support type 1. Anti-LKM1 supports type 2, which occurs particularly in children. Diagnosis also uses other findings and exclusion of alternatives.
Official College Textbook – Digestive Disorders – Part 2, pp. 115–117
Recall the diagnostic and management pathway from memory.
Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.
- Elevated ALT/AST → assess INR, glucose, symptoms and exposure history
- Exclude infection and metabolic/drug causes → IgG and age-appropriate autoantibodies
- AIH suspected → histology when safe, assess biliary overlap if indicated
- Confirmed → steroid induction with a tailored maintenance plan → monitor remission/relapse and complications